Are critical normal gene products in cancer cells the real therapeutic targets?


The majority of targets for rational anti-cancer drug development available at present have been defined by studies of early carcinogenesis. In this situation, mutations resulting in altered expression or structure of gene products, in the context of a relatively normal diploid background, provide the cell with a growth advantage. In contrast to cells… (More)